What is HC Wainwright’s Forecast for ABOS FY2029 Earnings?

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) – Stock analysts at HC Wainwright issued their FY2029 earnings per share estimates for Acumen Pharmaceuticals in a research report issued to clients and investors on Friday, March 28th. HC Wainwright analyst A. Fein anticipates that the company will earn ($2.03) per share for the year. HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Acumen Pharmaceuticals’ current full-year earnings is ($1.56) per share.

Acumen Pharmaceuticals (NASDAQ:ABOS) last posted its earnings results on Thursday, March 27th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.15).

Separately, UBS Group cut their target price on Acumen Pharmaceuticals from $6.00 to $4.00 and set a “buy” rating on the stock in a research note on Friday.

Acumen Pharmaceuticals Trading Down 3.3 %

Shares of ABOS stock opened at $1.19 on Monday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.43 and a current ratio of 10.43. The company has a market capitalization of $71.50 million, a price-to-earnings ratio of -0.86 and a beta of 0.02. Acumen Pharmaceuticals has a 52-week low of $1.10 and a 52-week high of $4.06. The company has a 50-day simple moving average of $1.38 and a two-hundred day simple moving average of $1.98.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Susquehanna Fundamental Investments LLC bought a new stake in Acumen Pharmaceuticals in the 4th quarter valued at about $25,000. Clune & Associates LTD. bought a new stake in shares of Acumen Pharmaceuticals in the fourth quarter valued at approximately $28,000. Intech Investment Management LLC bought a new stake in shares of Acumen Pharmaceuticals in the fourth quarter valued at approximately $32,000. Tower Research Capital LLC TRC boosted its holdings in Acumen Pharmaceuticals by 427.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 20,624 shares of the company’s stock worth $35,000 after buying an additional 16,714 shares during the period. Finally, SG Americas Securities LLC boosted its holdings in Acumen Pharmaceuticals by 44.2% in the 4th quarter. SG Americas Securities LLC now owns 25,631 shares of the company’s stock worth $44,000 after buying an additional 7,859 shares during the period. Hedge funds and other institutional investors own 71.01% of the company’s stock.

Insider Transactions at Acumen Pharmaceuticals

In other Acumen Pharmaceuticals news, CEO Daniel Joseph Oconnell sold 47,778 shares of the stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $1.84, for a total transaction of $87,911.52. Following the completion of the transaction, the chief executive officer now directly owns 454,707 shares of the company’s stock, valued at approximately $836,660.88. This represents a 9.51 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Matt Zuga sold 28,902 shares of the firm’s stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $1.72, for a total value of $49,711.44. Following the completion of the sale, the chief financial officer now directly owns 231,744 shares of the company’s stock, valued at $398,599.68. This represents a 11.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 131,526 shares of company stock worth $233,124 in the last ninety days. Company insiders own 7.10% of the company’s stock.

Acumen Pharmaceuticals Company Profile

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.